IMV - Earnings announcements

- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be

IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2022. "IMV worked diligently to deliver on our clinical goals in the third quarter. We restructured the business to facilitate the achievement of these objectives and remain on track to present meaningful clinical data early next year," said Andrew Hall, Chief Executive Officer of IMV. "We expect 2023 to be a potentially transformative year for IMV, w

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, November 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 third quarter financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast by registering on IMV website: https://ir.imv-inc.com/events-and-presentations. The webcast will be rec

Patient recruitment in the Phase 2B VITALIZE DLBCL trial of MVP-S plus Keytruda continues to track well, with first results expected in Q3 2022. Matthew J. Matasar, MD from Memorial Sloan Kettering Cancer Center, has joined VITALIZE as lead principal investigator of the study. First patient dosed in the Phase 2B AVALON platinum-resistant ovarian cancer trial of MVP-S plus intermittent low-dose cyclophosphamide, with early data expected in 1H 2023. IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its

IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 second quarter financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast by registering on IMV website: https://ir.imv-inc.com/events-and-presentations

Positive clinical results in bladder cancer were presented at the AACR annual meeting, including 2 confirmed complete responses (CRs) and 3 partial responses (PRs) per RECIST v1.1; CRs and PRs were observed in patients previously treated with checkpoint inhibitors; Treatment with MVP-S/CPA and pembrolizumab was well-tolerated with mostly grade 1-2 injection site reactions, and no severe adverse events attributed to MVP-S; New data were presented about DPX-based therapies' mechanism of action. Results from preclinical and clinical studies demonstrate that Natural Killer (NK) cells are also involved in the anti-cancer efficacy of DPX-based therapy. Michael P. Bailey was appointed

IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company's 2022 first quarter financial and operational results. Financial analysts are invited to join the conference call by dialing 1-844-461-9932 (U.S. and Canada) or 1-636-812-6632 (international) and using the conference ID: 5396906 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 17, 2022, at 8:00 a.m. ET to discuss the company's 2021 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by dialing 1-844-461-9932 (U.S. and Canada) or 1-636-812-6632 (international) and using the conference ID: 5049587 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentatio

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while preserving patients' quality of life today announced that it will hold a conference call and webcast on Thursday, November 11, 2021 at 8:00 a.m. ET to discuss the company's third quarter 2021 financial and operational results. Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) and using the conference ID: 7079735 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.co

IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, announced today that it will hold a conference call and webcast on Wednesday, August 11, 2021 at 8:00 a.m. ET to discuss the company's second quarter 2021 financial and operational results. Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) and using the conference ID: 2877244 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast wil